Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Royalty Pharma plc RPRX

Set alert

Price alert · RPRX

All alert types
66.52 USD -0.66 -0.98%

At close

66.51 -0.01 -0.02%

Pre-market · Nov 3, 7:12 AM ET

Bid
66.52 × 2
Ask
66.53 × 2
66.43 Day range 67.10
36.03 52-week range 67.71
YTD
+72.15%
1 year
+78.34%
Open
66.97
Prev close
67.18
Mkt cap
38.44B
Vol
2.87M
Avg vol
3.08M
EPS
1.88
P/E
35.38
Div yield
1.43%
More statistics
Low
66.43
High
67.10
Forward P/E
11.45
Beta
0.36
Short ratio
4.30
Inst. own
90.20%
Dividend
0.94
Ex-div date
Nov 12, 2026
Earnings
Nov 4, 2026
50-d avg
60.28
200-d avg
53.22
1y target
65.38

3M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Aug 5, 2026Earnings: 1.32; estimate 1.27; surprise 3.94%
  • Aug 7, 2026Rating: JP Morgan · Overweight → Overweight
  • Aug 14, 2026Dividend: 0.235
  • Sep 8, 2026Rating: TD Cowen · Buy → Buy
  • Oct 7, 2026Rating: Morgan Stanley · Overweight → Overweight
Signals (12)
NameDateAgo
RSI: OverboughtOct 22, 20261 week ago
SMA: BullishOct 15, 20262 weeks ago
SMA: BullishOct 14, 20262 weeks ago
MACD: Buy SignalOct 14, 20262 weeks ago
SMA: BearishSep 10, 20261 month ago
SMA: BearishSep 10, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
MACD: Buy SignalAug 17, 20262 months ago
SMA: BullishAug 10, 20262 months ago
SMA: BearishAug 6, 20262 months ago
SMA: BullishAug 4, 20263 months ago
SMA: BearishAug 3, 20263 months ago

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 65.38 -1.7% downside
Target (low)
61.00
Target (mean)
65.38
Target (high)
70.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy5
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 8
  • 1 month ago 8
  • 2 months ago 8

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

RPRX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter1.181.15 – 1.221.17+0.6%884.84M+8.7%6
Next quarter1.521.39 – 1.631.47+3.8%941.99M+7.8%5
Current year5.325.17 – 5.444.83+10.2%3.51B+7.7%6
Next year5.815.31 – 6.235.32+9.2%3.82B+9.1%6

Upgrades and downgrades

The latest rating changes

RPRX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 7, 2026Morgan StanleyMaintainedOverweightOverweight
Sep 8, 2026TD CowenMaintainedBuyBuy
Aug 7, 2026JP MorganMaintainedOverweightOverweight
Jul 13, 2026TD CowenMaintainedBuyBuy
May 7, 2026CitigroupMaintainedBuyBuy
May 7, 2026JP MorganMaintainedOverweightOverweight
Apr 21, 2026UBSMaintainedBuyBuy
Apr 10, 2026Morgan StanleyMaintainedOverweightOverweight
Jan 30, 2026UBSUpgradeNeutralBuy
Jan 27, 2026CitigroupMaintainedBuyBuy
Dec 11, 2025TD CowenMaintainedBuyBuy
Oct 10, 2025Morgan StanleyMaintainedOverweightOverweight
Sep 30, 2025Goldman SachsInitiated—Buy
Jul 22, 2025CitigroupMaintainedBuyBuy
Jul 10, 2025Morgan StanleyMaintainedOverweightOverweight
Oct 25, 2024CitigroupMaintainedBuyBuy
Aug 14, 2024Goldman SachsMaintainedBuyBuy
Jul 11, 2024Morgan StanleyMaintainedOverweightOverweight
Jun 3, 2024UBSDowngradeBuyNeutral
Apr 12, 2024B of A SecuritiesMaintainedBuyBuy
Feb 20, 2024JP MorganMaintainedOverweightOverweight
Feb 20, 2024Goldman SachsMaintainedBuyBuy
Nov 9, 2023Morgan StanleyMaintainedOverweightOverweight
Oct 11, 2023Morgan StanleyMaintainedOverweightOverweight
Aug 9, 2023Morgan StanleyMaintainedOverweightOverweight
Jul 11, 2023Morgan StanleyReiteratedOverweightOverweight
May 10, 2023Morgan StanleyMaintained—Overweight
Apr 10, 2023Morgan StanleyMaintained—Overweight
Apr 6, 2023Tigress FinancialReiterated—Buy
Feb 16, 2023UBSMaintained—Buy